{"id":519817,"date":"2021-07-29T08:03:47","date_gmt":"2021-07-29T12:03:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/"},"modified":"2021-07-29T08:03:47","modified_gmt":"2021-07-29T12:03:47","slug":"oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/","title":{"rendered":"Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results"},"content":{"rendered":"
\n

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2021 financial results after the\u00a0U.S.\u00a0financial markets close on\u00a0Thursday, August 5, 2021. Oncternal\u2019s management will host a webcast at\u00a02:00 p.m. PT\u00a0(5:00 p.m. ET) to provide a comprehensive business update and discuss the Company\u2019s financial results.<\/p>\n

The live webcast of the call will be available online via a link from the \u201cInvestor Relations<\/u><\/a>\u201d page of the Company\u2019s website at\u00a0www.oncternal.com<\/u><\/a>,<\/u> and the call will be archived there for at least 30 days.<\/p>\n

\n
\n About Oncternal Therapeutics<\/strong>
\n <\/strong>\n <\/p>\n

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab<\/a>,<\/u> an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1\/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer, as well as a Phase 2 clinical trial of cirmtuzumab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed\/refractory CLL. Oncternal is also developing a chimeric antigen receptor T cell (CAR-T<\/u><\/a>) therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. The clinical pipeline also includes TK216<\/a>, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1\/2 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. More information is available at https:\/\/oncternal.com\/<\/u><\/a>.<\/p>\n

\n Oncternal Contacts:<\/strong>\n <\/p>\n

\n Company Contact<\/strong>
\n
Richard Vincent
858-434-1113
rvincent@oncternal.com<\/a><\/u><\/p>\n

\n Investor Contact<\/strong>
\n
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com<\/u><\/a><\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2021 financial results after the\u00a0U.S.\u00a0financial markets close on\u00a0Thursday, August 5, 2021. Oncternal\u2019s management will host a webcast at\u00a02:00 p.m. PT\u00a0(5:00 p.m. ET) to provide a comprehensive business update and discuss the Company\u2019s financial results. The live webcast of the call will be available online via a link from the \u201cInvestor Relations\u201d page of the Company\u2019s website at\u00a0www.oncternal.com, and the call will be archived there for at least 30 days. About Oncternal Therapeutics Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies … <\/p>\n

Continue reading “Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-519817","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2021 financial results after the\u00a0U.S.\u00a0financial markets close on\u00a0Thursday, August 5, 2021. Oncternal\u2019s management will host a webcast at\u00a02:00 p.m. PT\u00a0(5:00 p.m. ET) to provide a comprehensive business update and discuss the Company\u2019s financial results. The live webcast of the call will be available online via a link from the \u201cInvestor Relations\u201d page of the Company\u2019s website at\u00a0www.oncternal.com, and the call will be archived there for at least 30 days. About Oncternal Therapeutics Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies … Continue reading "Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-29T12:03:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODkwNiM0MzIwNzk1IzUwMDA3NDE2MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results\",\"datePublished\":\"2021-07-29T12:03:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\\\/\"},\"wordCount\":364,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODkwNiM0MzIwNzk1IzUwMDA3NDE2MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\\\/\",\"name\":\"Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODkwNiM0MzIwNzk1IzUwMDA3NDE2MQ==\",\"datePublished\":\"2021-07-29T12:03:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODkwNiM0MzIwNzk1IzUwMDA3NDE2MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODkwNiM0MzIwNzk1IzUwMDA3NDE2MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results - Market Newsdesk","og_description":"SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2021 financial results after the\u00a0U.S.\u00a0financial markets close on\u00a0Thursday, August 5, 2021. Oncternal\u2019s management will host a webcast at\u00a02:00 p.m. PT\u00a0(5:00 p.m. ET) to provide a comprehensive business update and discuss the Company\u2019s financial results. The live webcast of the call will be available online via a link from the \u201cInvestor Relations\u201d page of the Company\u2019s website at\u00a0www.oncternal.com, and the call will be archived there for at least 30 days. About Oncternal Therapeutics Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies … Continue reading \"Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-29T12:03:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODkwNiM0MzIwNzk1IzUwMDA3NDE2MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results","datePublished":"2021-07-29T12:03:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/"},"wordCount":364,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODkwNiM0MzIwNzk1IzUwMDA3NDE2MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/","name":"Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODkwNiM0MzIwNzk1IzUwMDA3NDE2MQ==","datePublished":"2021-07-29T12:03:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODkwNiM0MzIwNzk1IzUwMDA3NDE2MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODkwNiM0MzIwNzk1IzUwMDA3NDE2MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=519817"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519817\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=519817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=519817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=519817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}